Wall Street loves a good David versus Goliath story. But what happens when two Davids are battling entirely different giants? Rocket Lab reported $123 million in first-quarter 2025 revenue, reflecting ...
As we look ahead to 2025, a number of factors poise the clinical laboratory market for continued transformation. The post-COVID-19 landscape is reshaping the industry, presenting both challenges and ...
Investors in the commercial space industry are showing increased interest in Rocket Lab USA, Inc. (NASDAQ: RKLB). Due to its focus on innovation and market demands, the company has grown from a small ...
Rocket Lab reported 69% sales growth in its Q1 earnings report, but still missed analyst targets. Rocket Lab is growing sales nicely, but still isn't profitable. A big defense contract won in late ...
CEO Patrick Kaltenbach highlighted a strong finish to 2024 with excellent performance in laboratory products, particularly in Europe. He emphasized the company’s focus on long-term strategies, ...
Rocket Lab's stock has dropped by 40% since its July peak due to lower revenue growth and a more risk-averse market. The recent launch failure of the Electron rocket could lead to delays and increased ...
Investors in the commercial space industry are showing increased interest in Rocket Lab USA, Inc. (NASDAQ: RKLB). Due to its focus on innovation and market demands, the company has grown from a small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results